Zai Lab Limited reported second quarter 2026 financial results with total revenue of $106.3 million and a net loss of $50.8 million, or $0.05 per ordinary share. Net product revenue reached $105.8 million, reflecting an 11% sequential increase driven by stabilization of ZEJULA sales and double-digit volume growth for VYVGART. The company maintains a cash position of $717.5 million as of June 30, 2026. Pipeline updates include the receipt of Orphan Drug Designation from the FDA and EMA for zocilurtatug pelitecan (zoci) in neuroendocrine carcinomas, and the commercial launch of KarXT in mainland China for schizophrenia treatment. Zai Lab operates as a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines in oncology, immunology, neuroscience, and infectious disease.